Stockchase Opinions

Brian Rogers Wyeth WYE-N TOP PICK Jun 04, 2004

Have great new pharmaceutical products they will bring into the market in the 2006/2012 timeframe. 14 X earnings and 2 1/2 percent yield. High quality.
$36.130

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

DON'T BUY
All the big pharma companies are taking out a lot of costs. The problem is the pipeline is pretty lean, visability is lean. Maybe a little bit of a short term trade up to reward them for the reduced cost structure. Not significant.
BUY
All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be.
BUY
Pharmaceutical sector is trading at very low valuations. Good growth profile and good portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does.